Clinical Study on the Efficacy of Lamivudine for Chronic Hepatitis B

Objective: To evaluate the clinical efficacy and safety of lamivudine for chronic hepatitis B.Method: 142 patients had chronic HBV infection were randomly divided into two groups,while being treated with liver protecting medicines and routine treatments,in which 75 patients received lamivudine 100mg once daily for twelve months. Result: After twelve months,the symptoms recurrence in treatment group was 2.67%(2/75),which was significantly lower than the control group 29.85%(20/67)(P0.01).Patients with elevated ALT levels at baseline became normal in 86.67%(65/75) of the treatment group compared with the control group were only 67.16%(45/67)(P0.01).The HbeAg negative conversion and HbeAg/anti HbeAg seroconversion of treatment group were respectively 28%(21/75) and 24%(18/75),which were significantly higher than the control group 10.45%(7/67) and 5.95%(4/67)(P0.01).The negative for HBV-DNA in treatment group was 85.33%(64/75) compare with the control group 16.42%(11/67)(P0.01).The overall incidences of adverse events of two groups were similar.Conclusion: Lamivudine is effective in improving symptoms,decreasing ALT and clearance of virus index of chronic hepatitis B.